Cargando…

Effect of arsenic trioxide plus etoposide, solumedrol, high‑dose cytarabine and cisplatin chemotherapy on the treatment of relapsed or refractory ALK+ anaplastic large cell lymphoma

It has been reported that arsenic trioxide (ATO) regulates lymphoma cell cycle, apoptosis, autophagy and mitochondrial activity, while it synergizes with other cytotoxic agents. In addition, ATO targets anaplastic lymphoma kinase (ALK)-fusion oncoprotein to repress anaplastic large cell lymphoma (AL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Yi, Lu, Huina, Dong, Yan, Xiu, Bing, Liang, Aibin, Zhang, Wenjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193373/ https://www.ncbi.nlm.nih.gov/pubmed/37216160 http://dx.doi.org/10.3892/ol.2023.13854

Ejemplares similares

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma
por: Devi, Kanta, et al.
Publicado: (2023)

P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY
por: Garcia-Sanz, R., et al.
Publicado: (2022)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma
por: Paszkiewicz‐Kozik, Ewa, et al.
Publicado: (2022)

Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
por: Heidegger, Simon, et al.
Publicado: (2014)

High Efficacy of Stem Cell Mobilization With Etoposide+Cytarabine Plus G-CSF in Patients With Multiple Myeloma
por: Zhu, Zhijuan, et al.
Publicado: (2022)

Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
por: Kim, Ki-Hyang, et al.
Publicado: (2009)

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
por: Konopleva, Marina Y., et al.
Publicado: (2022)

Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation
por: Frankiewicz, Andrzej, et al.
Publicado: (2018)

P1143: ZANUBRUTINIB PLUS CYTARABINE IN PATIENTS WITH REFRACTORY/RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Lin, Zhiguang, et al.
Publicado: (2023)

Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma
por: Knörr, Fabian, et al.
Publicado: (2022)

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
por: Xie, Lu, et al.
Publicado: (2021)

Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial
por: Zhang, Li, et al.
Publicado: (2018)

BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
por: Wu, Ran, et al.
Publicado: (2023)

Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review
por: He, Xuepeng, et al.
Publicado: (2014)

A Case of Successful Intrapleural Chemotherapy with Cisplatin Plus Cytarabine for Intractable Malignant Pleural Effusion
por: Moon, Yong Wha, et al.
Publicado: (2007)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin's Lymphoma
por: Pangarsa, Eko A., et al.
Publicado: (2021)

Management of relapse in acute promyelocytic leukaemia treated with up‐front arsenic trioxide‐based regimens
por: Fouzia, N. A., et al.
Publicado: (2020)

Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia
por: Li, Ning, et al.
Publicado: (2012)

The clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma
por: Li, Xin, et al.
Publicado: (2015)

Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature
por: Hu, Steve, et al.
Publicado: (2016)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020)

Evidences of Protective Potentials of Microdoses of Ultra-High Diluted Arsenic Trioxide in Mice Receiving Repeated Injections of Arsenic Trioxide
por: Banerjee, Pathikrit, et al.
Publicado: (2011)

An Exceptionally Favorable Response to Etoposide and Cisplatin
por: Valecha, Gautam, et al.
Publicado: (2015)

Successful concurrent chemoradiotherapy with cisplatin plus etoposide after incomplete resection for advanced thymic carcinoma
por: Han, Ling, et al.
Publicado: (2019)

Four Cycles of Etoposide plus Cisplatin for Patients with Good‐Risk Advanced Germ Cell Tumors
por: Funt, Samuel A., et al.
Publicado: (2021)

In silico mechanisms of arsenic trioxide-induced cardiotoxicity
por: Li, Yacong, et al.
Publicado: (2022)

Arsenic trioxide as an inducer of immunogenic cell death
por: Kepp, Oliver, et al.
Publicado: (2023)

Immunological consequences of arsenic trioxide-induced necrosis
por: Gavali, Shubhangi, et al.
Publicado: (2023)

Retracted: Evidences of Protective Potentials of Microdoses of Ultra-High Diluted Arsenic Trioxide in Mice Receiving Repeated Injections of Arsenic Trioxide
por: Medicine, Evidence-Based Complementary and Alternative
Publicado: (2021)

Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large Cell Lymphoma
por: Verran, Julian, et al.
Publicado: (2022)

Arsenic trioxide induces gasdermin E mediated pyroptosis in astroglioma cells
por: Wang, Jingling, et al.
Publicado: (2020)

Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report
por: Emmons, Gregory S, et al.
Publicado: (2012)

Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance
por: Chendamarai, Ezhilarasi, et al.
Publicado: (2015)

Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse
por: Kulkarni, Uday Prakash, et al.
Publicado: (2023)

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study
por: Halpern, Anna B., et al.
Publicado: (2017)

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer
por: Kim, Dong-Wan, et al.
Publicado: (2019)

Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction
por: Li, Hecheng, et al.
Publicado: (2009)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r5jjit65jhs7rbsp3eknpbqt88